Citadel Advisors’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-71,700
| Closed | -$1.44M | – | 14320 |
|
|
2026
Q1 | $1.44M | Buy |
71,700
+43,700
| +156% | +$704K | ﹤0.01% | 6802 |
|
|
2025
Q4 | $452K | Buy |
+28,000
| New | +$371K | ﹤0.01% | 9274 |
|
|
2025
Q2 | – | Sell |
-42,400
| Closed | -$489K | – | 13854 |
|
|
2025
Q1 | $489K | Buy |
42,400
+28,900
| +214% | +$295K | ﹤0.01% | 8523 |
|
|
2024
Q4 | $114K | Buy |
13,500
+11,600
| +611% | +$120K | ﹤0.01% | 11265 |
|
|
2024
Q3 | $22K | Sell |
1,900
-7,400
| -80% | -$93.1K | ﹤0.01% | 12711 |
|
|
2024
Q2 | $110K | Sell |
9,300
-6,300
| -40% | -$73.5K | ﹤0.01% | 10790 |
|
|
2024
Q1 | $185K | Sell |
15,600
-34,500
| -69% | -$460K | ﹤0.01% | 10438 |
|
|
2023
Q4 | $614K | Buy |
50,100
+35,600
| +246% | +$324K | ﹤0.01% | 7656 |
|
|
2023
Q3 | $140K | Buy |
14,500
+13,900
| +2,317% | +$142K | ﹤0.01% | 10468 |
|
|
2023
Q2 | $5.4K | Sell |
600
-100
| -14% | -$922 | ﹤0.01% | 13505 |
|
|
2023
Q1 | $5.5K | Sell |
700
-3,900
| -85% | -$29.1K | ﹤0.01% | 13865 |
|
|
2022
Q4 | $31.1K | Sell |
4,600
-202,700
| -98% | -$1.09M | ﹤0.01% | 12704 |
|
|
2022
Q3 | $3.01M | Sell |
207,300
-168,400
| -45% | -$2.35M | ﹤0.01% | 4810 |
|
|
2022
Q2 | $3.7M | Buy |
375,700
+304,200
| +425% | +$3.36M | ﹤0.01% | 4373 |
|
|
2022
Q1 | $1.05M | Buy |
+71,500
| New | +$1.03M | ﹤0.01% | 7570 |
|
|
2021
Q3 | – | Sell |
-24,100
| Closed | -$577K | – | 14250 |
|
|
2021
Q2 | $577K | Sell |
24,100
-18,100
| -43% | -$474K | ﹤0.01% | 9732 |
|
|
2021
Q1 | $1.08M | Sell |
42,200
-24,700
| -37% | -$649K | ﹤0.01% | 7919 |
|
|
2020
Q4 | $1.27M | Buy |
+66,900
| New | +$1.15M | ﹤0.01% | 6283 |
|
Other funds holding KALV
Citadel Advisors's KALV Position: Q2 2026 in Review
Citadel Advisors sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 97,726 shares — an estimated $1.97M sold.
Citadel Advisors first reported a position in KALV in Q2 2015 and held it in 24 quarters. The position peaked at $9.6M in Q4 2023. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Citadel Advisors reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Citadel Advisors sold 97,726 KalVista Pharmaceuticals shares in Q2 2026, an estimated $1.97M.
- Citadel Advisors first reported a position in KalVista Pharmaceuticals in Q2 2015 and held it in 24 quarters.
- Citadel Advisors's KalVista Pharmaceuticals position peaked at $9.6M in Q4 2023.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.